New oral pill TLL018 aims to clear psoriasis plaques in phase 2 trial

NCT ID NCT05772520

Completed Disease control Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether an experimental oral drug called TLL018 can improve skin clearance in adults with moderate-to-severe plaque psoriasis. Participants receive one of two doses of TLL018 or a placebo for 12 weeks. The main goal is to see if at least 75% of skin plaques clear up, as measured by the Psoriasis Area and Severity Index (PASI-75).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TLL018 tablets
What this could lead to: If successful, TLL018 could offer a new oral treatment option for people with moderate-to-severe plaque psoriasis, potentially reducing skin plaques and symptoms.
What could go wrong: This is an early phase 2 trial with only 82 participants, so results may not apply broadly. The drug may not prove effective or could have side effects not yet identified.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLAQUE PSORIASIS

Contacts and locations

Show contact details

Locations

Acclaim

Sugar Land, Texas, 77479, United States
Altus Research

Lake Worth, Florida, 33461, United States
Amicis Research Center

Northridge, California, 91324, United States
Anchor Medical Research, LLC (Core Clinical Trials)

Miami, Florida, 33176, United States
Austin Institute for Clinical Research

Pflugerville, Texas, 78660, United States
CNS - Jacksonville

Jacksonville, Florida, 32256, United States
CNS - Orlando SODO

Jacksonville, Florida, 32256, United States
CRCC

Charleston, South Carolina, 29407, United States
Cahaba

Birmingham, Alabama, 35244, United States
D&H Doral Research Center LLC

Doral, Florida, 33122, United States
Derm Research

Austin, Texas, 78759, United States
DermDox

Sugarloaf, Pennsylvania, 18249, United States
Dermatology Associates of Knoxville

Knoxville, Tennessee, 37909, United States
ForCare Medical (CenExcel)

Tampa, Florida, 33613, United States
Grekin Skin

Warren, Michigan, 48088, United States
IMA Clinical Research

Monroe, Louisiana, 71201, United States
Integrated Clinical Trial Services, Inc

Des Moines, Iowa, 50265, United States
Integrative Skin

Sacramento, California, 95815, United States
Lawrence Green

Rockville, Maryland, 20850, United States
Life Clinical Trials

Coral Springs, Florida, 33071, United States
Metro Boston

Brighton, Massachusetts, 02135, United States
Metropolis Derm

Los Angeles, California, 90017, United States
Minnesota Clinical Study Center

New Ulm, Minnesota, 55112, United States
Mount Sinai

New York, New York, 10003, United States
Moy, Fincher, Chipps

Beverly Hills, California, 90210, United States
Oakland Hills Dermatology

Auburn Hills, Michigan, 48326, United States
Palm Beach

DeLand, Florida, 33484, United States
Progressive Clinical Research Group, Inc.

San Antonio, Texas, 78213, United States
Remington-Davis, Inc.

Columbus, Ohio, 43215, United States
Reserka Research

Miami, Florida, 33176, United States
Revival Research Institute

Troy, Michigan, 48084, United States
Sadick Research Group

New York, New York, 10075, United States
Skin Surgical

San Diego, California, 92117, United States
Studies in Dermatology, LLC

Cypress, Texas, 77433, United States
Sweet Hope Research Specialty, Inc

Hialeah, Florida, 33016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.